CSIMarket Company Name, Ticker, Suppliers, else..
 
Bio path Holdings inc   (BPTH)
 
Price: $0.0002 $0.00 -60.000%
Day's High: $0.00019999999494757503 Week Perf: 0.00
Day's Low: $ 0.00 30 Day Perf: -99.33 %
Volume (M): 16,001 52 Wk High: $ 0.11
Volume (M$): $ 0 52 Wk Avg: $0.05
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 9
 Employees 9
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Bio-Path Holdings Inc. is a clinical-stage biotechnology company that focuses on developing therapeutic products to treat cancer and other diseases. It is headquartered in Houston, Texas. The company's proprietary technology platform, known as DNAbilize, uses synthetic oligonucleotides to deliver cancer-fighting drugs directly to cancer cells. This targeted approach is designed to enhance the effectiveness of the drugs while minimizing side effects. Bio-Path Holdings has a pipeline of drug candidates in various stages of development, targeting different types of cancer, including acute myeloid leukemia and solid tumors. The company is committed to advancing innovative treatments for patients with unmet medical needs in the oncology field.


   Company Address: 625 Stanwix St Pittsburgh 15222 PA
   Company Phone Number: 708-0750   Stock Exchange / Ticker: BPTH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY        6.85% 
ARWR   -0.84%    
PTCT   -4.13%    
REGN        0.41% 
SRPT   -7.16%    
VRTX        3.51% 
• View Complete Report
   



Clinical Study

Expanding Horizons Bio-Path Holdings Advances BP1001-A as a Novel Therapeutic for Obesity in Type 2 Diabetes Patients

Published Thu, May 1 2025 12:39 PM UTC

In a notable development for the biopharmaceutical sector, Bio-Path Holdings, Inc. (NASDAQ: BPTH) has announced it has achieved its third pre-clinical milestone in its efforts to advance BP1001-A, a promising treatment aimed at tackling obesity, particularly in patients with Type 2 diabetes. This innovative program signifies a pivotal shift in the company’s focus, as it ma...
Clinical Study

Bio-Path Holdings Pioneering Solutions for Obesity in Type 2 Diabetes Through Grb2 Innovation,

Published Mon, Dec 30 2024 2:07 AM UTC

Navigating New Frontiers: Bio-Path Holdings and the Quest for Innovative Obesity Treatments in Type 2 Diabetes In an era where chronic diseases such as obesity and Type 2 diabetes have reached epidemic proportions, the quest for effective treatments is more urgent than ever. Amidst this healthcare crisis, Bio-Path Holdings Inc. has emerged as a promising player with its inno...
Clinical Study

Bio-Path Holdings Unveils Promising Findings for BP1001-A in Treating Obesity and Type 2 Diabetes, Amidst Ongoing Sha...

Published Thu, Dec 19 2024 12:00 PM UTC

Bio-Path Holdings Advances BP1001-A: A New Prospect for Treating Obesity in Type 2 Diabetes Patients Bio-Path Holdings Inc has announced the commencement of preclinical testing for its new therapeutic candidate, BP1001-A, which may offer a promising solution in enhancing insulin sensitivity for individuals suffering from obesity and type 2 diabetes. The recent preclinical st...
Clinical Study

Expanding Horizons Bio-Path Holdings Ventures Into Obesity Treatment with Innovative DNAbilize Technology

Published Tue, Oct 8 2024 11:00 AM UTC

Exploring New Frontiers in Obesity TreatmentIn a groundbreaking development, Bio-Path Holdings, Inc. a biotechnology firm renowned for its innovative cancer treatment solutions, announced the initiation of a new therapeutic program aimed at addressing obesity and related metabolic diseases. This initiative marks a significant milestone for the company as it utilizes its pro...
Stock Market Announcement

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Published Thu, Oct 10 2024 9:24 PM UTC

Bio-Path Holdings Secures $4.0 Million in Recent Private Placement: An Analysis of Their Financial Maneuvers and Market Position Bio-Path Holdings, Inc. (NASDAQ: BPTH), a Houston-based biotechnology company focused on developing innovative targeted nucleic acid cancer therapies with its proprietary DNAbilize liposomal delivery and antisense technology, recently announced a...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0
Working Capital Ratio 0.07
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.09 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -966,111
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.